Scrip
>>Business

VectivBio Seeks Slice Of Short Bowel Syndrome Market

As Offering Brings In $125m

14 Oct 2022

The Switzerland-headquartered group believes it has a potentially best-in-class GLP-2 agonist on its hands with apraglutide, which has proved effective in a subgroup of patients that do not benefit from standard of care Gattex.

High jump — Apraglutide clears clinical bar • Source: Archive

Having just raised $125m and presented promising mid-stage data on apraglutide, VectivBio Holding AG is making strides in its bid to become the leading player in the short bowel syndrome (SBS) space currently dominated by Takeda Pharmaceutical Co. Ltd.'s Gattex.

The Swiss biotech, established in May 2019 as a spin-off from Therachon Holding AG following the latter's $810m acquisition...